Effects of 4-week administration of simvastatin in different doses on heart rate and blood pressure after metoprolol injection in normocholesterolaemic and normotensive rats

Archives of Medical Science

Volumn 8, Issue 1, 2012, Pages 17-21

  Owczarek, Jacek ^a   Jasiñska, Magdalena ^a   Wejman, Irena ^a   Kurczewska, Urszula ^a   Orszulak Michalak, Daria ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Blood pressure; Heart rate; Metoprolol; Rats; Simvastatin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLCELLULOSE; METOPROLOL; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HEART RATE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 84858136589     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.27275     Document Type: Article

References (26)

1. Owczarek J, Jasińska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 2005; 57: 23-34. (Pubitemid 40601538)
2. Wainwright G, Mascitelli L, Goldstein MR. Cholesterol lowering therapy and cell membranes. Stable plaque at the expense of unstable membranes? Arch Med Sci 2009; 5: 289-95.
3. Jasińska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007; 59: 483-99.
4. Angelopoulos J, Krassakopoulos N, Nathanson R, Bou kas S, Sampalis JS. Co-administration of ezetimibe and a statin in management of dyslipidemias: meta-analysis of clinical trials. Arch Med Sci 2009; 5: 347-63.
5. Nette AF, Abraham G, Ungemach FP, et al. Interaction between simvastatin and metoprolol with respect to cardiac beta-adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients. Naunyn Schmiedebergs Arch Pharmacol 2005; 372: 115- 24.
6. Mühlhäuser U, Zolk O, Rau T, Münzel F, Wieland T, Eschenhagen T. Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits. FASEB J 2006; 20: 785-7. (Pubitemid 46671215)
7. Owczarek J, Jasińska M, Orszulak-Michalak D. Dose-dependent influence of two-week administration of simvastatin and metoprolol injection on the blood pressure in normocholesterolemic rats. Acta Pol Pharm 2008; 65: 147-51. (Pubitemid 351578443)
8. Owczarek J, Jasińska M, Orszulak-Michalak D. Interaction between different doses of simvastatin after two-week administration and metoprolol injection on the heart rate in normocholesterolemic rats. Acta Pol Pharm 2008; 65: 141-5. (Pubitemid 351578442)
9. Wierzbicki AS, Chowienczyk PJ, Cockcroft JR, et al. Cardiovascular risk factors and endothelial dysfunction. Clin Sci (London) 2004; 107: 609-15. (Pubitemid 39627208)
10. Strazzullo P, D'Elia L, Versiero M. Response to up-regulation of nitric oxide, inhibition of oxidative stress, and anti-hypertensive effects of statins. Hypertension 2007; 49: 792-8.
11. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects form ischaemic stroke in mice. Brain Res 2002; 942: 23-30. (Pubitemid 34597065)
12. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9. (Pubitemid 28294580)
13. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96. (Pubitemid 32008567)
14. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.
15. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-5. (Pubitemid 34234125)
16. Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis 2001; 155: 245-50. (Pubitemid 32167146)
17. Muntz KH, Sternweis PC, Gilman AG, Mumby SM. Influence of gamma subunit prenylation and association of guanine nucleotide-binding regulatory proteins with membranes. Mol Biol Cell 1992; 3: 49-61. (Pubitemid 23094251)
18. Simonds WF, Butrynski JE, Gautam N, Unson CG, Spiegel AM. G-protein beta gamma dimmers. Membrane targeting requires subunit coexpression and intact gamma C-A-A-X domain. J Biol Chem 1991; 266: 5363-6. (Pubitemid 21909500)
19. Chiloeches A, Lasa M, Brihuega F, Montes A, Toro MJ. Effects of lovastatin on adenylyl cyclase activity and G proteins in GH4C1 cells. FEBS Lett 1995; 361: 46-50.
20. McLeish KR, Lederer ED, Klein JB. Role of isoprenoid metabolism in chemotactic peptide receptor-mediated G protein activation. Biochem Biophys Res Commun 1993; 197: 763-70. (Pubitemid 24034635)
21. Murga C, Esteban N, Ruiz-Gomez A, Mayor F Jr. The basal subcellular distribution of beta-adrenergic receptor kinase is independent of G-protein beta gamma subunits. FEBS Lett 1997; 409: 24-8. (Pubitemid 27248559)
22. Nüsse O, Neer EJ. Localization of G alpha 0 to growth cones in PC12 cells: role of G alpha 0 association with receptors and G beta gamma. J Cell Sci 1996; 109: 221-8.
23. Sari R, Nemeth J, Porszasz R, et al. Impairment by lovastatin of neural relaxation of the rabbit sphincter of Oddi. Eur J Pharmacol 2001; 432: 91-7. (Pubitemid 33153137)
24. Golomb BA, Ritchie JB, Criqui MH, Dimsdale JE. Statins lower blood pressure: results from the UCSD Statin Study. Circulation 2004; 110: III-402.
25. Poulter N, Sever PS. Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Circulation 2004; 110: III-402.
26. Sacks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9. (Pubitemid 26338729)